Mechanisms of cholinesterase inhibition in senile dementia of the alzheimer type: Clinical, pharmacological, and therapeutic aspects
- 1 January 1988
- journal article
- review article
- Published by Wiley in Drug Development Research
- Vol. 12 (3-4) , 163-195
- https://doi.org/10.1002/ddr.430120302
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer TypeNew England Journal of Medicine, 1986
- Physostigmine restores3H-acetylcholine efflux from Alzheimer brain slices to normal levelJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1986
- Physostigmine effects in Alzheimer's disease: Relationship to dementia severityLife Sciences, 1986
- Muscarinic receptor alterations as a mechanism of anticholinesterase toleranceToxicology and Applied Pharmacology, 1983
- Memory Enhancement with Oral Physostigmine in Alzheimer's DiseaseNew England Journal of Medicine, 1983
- Clinical Response to Choline plus Piracetam in Senile Dementia: Relation to Red-Cell Choline LevelsNew England Journal of Medicine, 1981
- Cholinomimetic Treatment Fails to Improve Memory DisordersNew England Journal of Medicine, 1980
- Enhancement of Memory by PhysostigmineNew England Journal of Medicine, 1979
- Choline in Alzheimer's DiseaseNew England Journal of Medicine, 1979
- Effect of atropine and/or physostigmine on cerebral acetylcholine in rats poisoned with SomanLife Sciences, 1978